Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 40 of the 56 sources its claims cite were checked for support.
Abstract
BACKGROUND: Heart failure with preserved ejection fraction is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in persons with obesity. No therapies have been approved to target obesity-related heart failure with preserved ejection fraction. METHODS: We randomly assigned 529 patients who had heart failure with preserved ejection fraction and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or higher to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks. The dual primary end points were the change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations) and the change in body weight. Confirmatory secondary end points included the change in the 6-minute walk distance; a hierarchical composite end point that included death, heart failure events, and differences in the change in the KCCQ-CSS and 6-minute walk distance; and the change in the C-reactive protein (CRP) level. RESULTS: The mean change in the KCCQ-CSS was 16.6 points with semaglutide and 8.7 points with placebo (estimated difference, 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P<0.001), and the mean percentage change in body weight was -13.3% with semaglutide and -2.6% with placebo (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001). The mean change in the 6-minute walk distance was 21.5 m with semaglutide and 1.2 m with placebo (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001). In the analysis of the hierarchical composite end point, semaglutide produced more wins than placebo (win ratio, 1.72; 95% CI, 1.37 to 2.15; P<0.001). The mean percentage change in the CRP level was -43.5% with semaglutide and -7.3% with placebo (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001). Serious adverse events were reported in 35 participants (13.3%) in the semaglutide group and 71 (26.7%) in the placebo group. CONCLUSIONS: In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF ClinicalTrials.gov number, NCT04788511.).
Overview
CoChat Summary
TL;DR
In STEP-HFpEF, once-weekly semaglutide 2.4 mg versus placebo in patients with heart failure with preserved ejection fraction and obesity improved heart failure symptoms/physical limitations, body weight, exercise function, a hierarchical composite outcome, and CRP over 52 weeks. Semaglutide also had fewer serious adverse events than placebo.
Key findings
- Dual primary end points: mean KCCQ-CSS change was 16.6 points with semaglutide vs 8.7 with placebo (estimated difference, 7.8 points; 95% CI, 4.8 to 10.9; P<0.001), and mean body weight changed by -13.3% vs -2.6% (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001).
- Confirmatory secondary end points: 6-minute walk distance changed by 21.5 m vs 1.2 m (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001); hierarchical composite win ratio was 1.72 (95% CI, 1.37 to 2.15; P<0.001); CRP changed by -43.5% vs -7.3% (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001).
- Safety: serious adverse events occurred in 35 participants (13.3%) with semaglutide vs 71 (26.7%) with placebo (P<0.001), driven mainly by fewer cardiac disorder events (7 [2.7%] vs 30 [11.3%]; P<0.001); discontinuation due to any adverse event occurred in 35 vs 14 participants, predominantly gastrointestinal events.
- Exploratory: adjudicated heart failure hospitalization or urgent visit occurred in 1 semaglutide participant vs 12 placebo participants (hazard ratio, 0.08; 95% CI, 0.00 to 0.42).
Methods
- Randomized, double-blind, placebo-controlled trial at 96 sites in 13 countries; 529 participants with HFpEF, BMI ≥30, LVEF ≥45%, NYHA class II–IV, KCCQ-CSS <90, and 6-minute walk distance ≥100 m were assigned 1:1 to once-weekly semaglutide 2.4 mg or placebo for 52 weeks plus 5-week follow-up.
- Dual primary end points were change in KCCQ-CSS and percentage change in body weight at week 52; confirmatory secondary end points included 6-minute walk distance, a hierarchical composite (death, heart failure events, KCCQ-CSS and 6-minute walk differences), and CRP.
- Efficacy was analyzed in the full analysis population using the treatment policy estimand; continuous end points used ANCOVA, the hierarchical composite used a win-ratio approach, and safety was analyzed in the as-treated safety population.
Limitations
- Stated in the paper: the number of non-White participants was low, which may limit generalizability; the trial was not adequately powered for clinical events such as heart failure hospitalizations/urgent visits; follow-up was limited to 1 year; specific glycated hemoglobin data were not collected beyond excluding diabetes; and SGLT2 inhibitor use was low.
- Evident from the text: the trial population was 95.8% White, median age 69 years, all with BMI ≥30, and patients with diabetes were excluded, so findings may not generalize to more diverse, younger, non-obese, or diabetes populations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Valid · 2 Not valid · 4 Not checked · 90 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that obesity and excess adiposity are not simply coexisting conditions but may play a role in the development and progression of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Background calls obesity a risk factor for incident heart failure, and the Discussion links severe obesity to more adverse outcomes and hospitalizations among patients who already have HFPEF. These findings support the hedged suggestion that obesity may matter beyond coexistence, but the paper does not establish a role for excess adiposity specifically in the development or progression of HFPEF; its HFPEF analysis concerns BMI and outcomes. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. source
The Discussion (page not provided) states that increased adiposity promotes conditions that contribute to HFpEF pathophysiology. The Conclusions (page not provided) add that adipose deposition may have adverse consequences for HFpEF. Together, these support the citing sentence’s hedged claim that adiposity may play a role rather than merely coexist with the disease. (LLM, conf=0.88)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The main text explicitly says that excess adipose tissue likely plays a pivotal role in the development and progression of HFpEF. It also describes evidence linking adiposity to incident HFpEF and adverse outcomes in established HFpEF. This supports the citing sentence’s hedged claim that obesity and excess adiposity may contribute rather than merely coexist. (LLM, conf=0.94)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5 describes obesity-related changes that can lead to HFpEF. Section 5.8.1 links visceral adiposity to the risk of developing HFpEF and reports that central adiposity is associated with worse outcomes in patients who have it. Together, these passages support the hedged claim that excess adiposity may contribute to development and progression. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that adipose tissue may play a pivotal role in the development, progression, and adverse outcomes of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports a U-shaped association between BMI and adverse outcomes in patients with HFpEF, and the paper describes obesity as a risk factor for developing heart failure generally. It does not establish a role for adipose tissue in HFpEF progression or specifically in its development; BMI is not a direct measure of adipose-tissue activity. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Partly supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says increased adiposity contributes to HFpEF pathophysiology and links abdominal fat to impaired exercise tolerance in older obese patients. This supports a possible role for adipose tissue, but the paper does not establish its role in HFpEF progression or in adverse clinical outcomes. (LLM, conf=0.85)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The paper’s main text explicitly says that excess adipose tissue likely plays a pivotal role in HFpEF development, progression, and adverse outcomes. It also identifies visceral adipose tissue as especially important in metabolic/obese HFpEF. (LLM, conf=0.95)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5.8.1 (page not provided) describes a pivotal role for visceral adipose tissue in obese HFpEF, linking it to both incident HFpEF risk and worse outcomes. Section 5.3 (page not provided) describes mechanisms by which epicardial adipose tissue may impair cardiac function and reports associations with greater disease severity and hospitalization or death. Together, these passages support the claim’s hedged wording. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Even when patients have well compensated heart failure with preserved ejection fraction and are in stable condition, they have markedly impaired objectively measured physical function. 34”
What the sources say
- Partly supportedcites [34] 34. Pandey A, Shah SJ, Butler J, et al. Exercise intolerance in older adults with heart failure with preserved ejection fraction: JACC state-of-the-art review. J Am Coll Cardiol 2021; 78: 1166-87. sourceExperimental — accuracy not yet measured
In ‘EI: A Key Manifestation of HFpEF’ (page unavailable), the review reports that objectively measured peak oxygen uptake is, on average, 35% lower in patients with HFpEF than in matched healthy controls. This supports marked impairment, but the passage does not establish that the patients were well-compensated and clinically stable. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our findings of substantial reductions in symptoms and physical limitations and improvements in exercise function that parallel a greater degree of weight loss with semaglutide than with placebo may offer insights into the long-standing controversy surrounding weight (and weight loss) in persons with heart failure. 8”
What the sources say
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“previous global clinical trial programs of agents such as SGLT2 inhibitors, sacubitrilvalsartan, and spironolactone for heart failure with preserved ejection fraction showed only modest changes in KCCQ scores (ranging from 0.5 to 2.3 points). 31-33”
What the sources say
- Partly supportedcites [31] 31. Butler J, Filippatos G, Jamal Siddiqi T, et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. Circulation 2022; 145: 184-93. sourceExperimental — accuracy not yet measured
The Discussion (page not available) reports modest KCCQ improvements in the TOPCAT spironolactone and PARAGON-HF sacubitril/valsartan trials, while the Results report modest improvements with the SGLT2 inhibitor empagliflozin. These passages support the overall characterization, but they do not establish the stated range of 0.5 to 2.3 points. (LLM, conf=0.86)
- Partly supportedcites [32] 32. Kosiborod MN, Bhatt AS, Claggett BL, et al. Effect of dapagliflozin on health status inpatients with preserved or mildly reduced ejection fraction. J Am Coll Cardiol 2023; 81: 460-73. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) describes the KCCQ benefit with dapagliflozin in DELIVER as modestly higher than that with empagliflozin in EMPEROR-PRESERVED, and mentions the sacubitril-valsartan PARAGON-HF trial. It does not establish the claimed 0.5–2.3-point range across those trials or report a corresponding spironolactone result. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [33] 33. Lewis EF, Kim HY, Claggett B, et al. Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2016; 9(3): e001937. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
45 more claims · 1 with their cited sources checked
Create a free account to see all 113 claims and every source verdict.
- Probably not a substantial claim. 33
- It may state two separate claims as one. 43
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and there is evidence that semaglutide 2.4 mg improves heart failure with preserved ejection fraction in individuals without diabetes by a potentially direct or indirect effect on epicardial adipose tissue (Kosiborod et al, 2023;Myasoedova et al, 2023).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Kosiborod et al, 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [65]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with HFpEF and obesity (with and without diabetes), semaglutide 2.4 mg once weekly for 52 weeks improved symptoms, physical function, exercise function and bodyweight compared to placebo (STEP HFpEF and STEP HFpEF DM clinical trials) [59,91].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the STEP-HFpEF trial, semaglutide treatment in patients with obesity-related HFpEF led to significant improvements in the 6-min walk distance (6MWD) and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), despite concurrent losses in lean mass [38].”
From Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“weight-loss interventions (eg, gastric bypass surgery and glucagon-like peptide-1 receptor agonists) can reduce the risk of incident HF and improve symptoms in patients with established HFpEF.16–20”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
39 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationO'Connor (2009) · doi:10.1001/jama.2009.454 · Cited by 2,173
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Self-citationHeart Failure With Preserved, Borderline, and Reduced Ejection Fraction
Shah, K. S., Xu, H., Matsouaka, R. A., Bhatt, D. L., Heidenreich, P. A., Hernandez, A. F., Devore, A. D., Yancy, C. W., & Fonarow, G. C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.074 · Cited by 1,110
Epidemiology of Heart Failure: A Contemporary Perspective
Roger, V. L. (2021) · Circulation Research · doi:10.1161/circresaha.121.318172 · Cited by 946
Kitzman, D. W., Brubaker, P., Morgan, T., Haykowsky, M., Hundley, G., Kraus, W. E., Eggebeen, J., & Nicklas, B. J. (2016) · JAMA · doi:10.1001/jama.2015.17346 · Cited by 921
Self-citationBordicchia, M., Liu, D., Amri, E.-Z., Ailhaud, G., Dessì-Fulgheri, P., Zhang, C., Takahashi, N., Sarzani, R., & Collins, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59701 · Cited by 872
Heart Failure With Preserved Ejection Fraction
Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.049 · Cited by 742
Self-citationEvaluation and management of heart failure with preserved ejection fraction
Borlaug, B. A. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0363-2 · Cited by 675
Self-citation
Cited by
Items 301–400 of 1,639
The Role of Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
Tzoumas, A., Tapp, D. N., Crousillat, D. R., Honigberg, M. C., Lozano, P. F. R., Aggarwal, N. R., Ebong, I., Briller, J. E., de Oliveira, G. M., Harrington, C. M., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102345 · Cited by 23
Keramida, K., López‐Fernández, T., Anker, M. S., Petrie, M. C., Ameri, P., Anderson, L. J., Bergler-Klein, J. K., Deswal, A. M., Farmakis, D. T., Ibáñez, B., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70005 · Cited by 24
Self-citationLin, Y., Wu, J., Lee, M.-C., Su, C.-Y., Toh, H. S., Chang, W., Chen, S.-Y., Kuo, F., Tang, H., & Liao, C. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae093 · Cited by 20
“54 These findings align with and extend current treatment guidelines, which suggest considering both drug classes for A SC VD patients, with a preference for SGLT2is in those with chronic kidney disease or heart failure.”
Siddiqi, T. J., Khan, M. S., Waqas, S. A., Spall, H. G. C. V., Shapiro, M. D., Fonarow, G. C., Januzzi, J. L., Afzal, A. M., Pandey, A., Butler, J., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70048 · Cited by 20
Self-citationA united vision for cardiovascular–kidney–metabolic health
Quaggin, S. E., & Magod, B. L. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00812-6 · Cited by 20
Linetzky, B., Sattar, N., Verma, S., Krumholz, H. M., Xie, C. C., Hoffmann, H. T., Zimner-Rapuch, S., Torcello-Gómez, A., & Stefanski, A. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02623 · Cited by 17
Self-citationImpact of DPP-4 Inhibitors in Patients with Diabetes Mellitus and Heart Failure: An In-Depth Review
Epelde, F. (2024) · Medicina · doi:10.3390/medicina60121986 · Cited by 22
Fudim, M., Litwin, S. E., Borlaug, B. A., Mohan, R. C., Price, M. J., Fail, P. S., Zirakashvili, T., Shaburishvili, T., Goyal, P., Hummel, S. L., et al. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.12.010 · Cited by 18
Self-citationMechanisms of exercise intolerance in heart failure with preserved ejection fraction (HFpEF)
Pecchia, B., Samuel, R., Shah, V., Newman, E., & Gibson, G. T. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10504-3 · Cited by 26
“Intriguingly, the use of glucagon-like peptide 1 receptor (GLP-1) agonists, which were originally developed for the treatment of diabetes mellitus and obesity, have been shown to improve exercise capacity in patients with HFpEF [127, 128].”
Metra, M., Tomasoni, D., Adamo, M., Amir, O., Anker, S. D., Bayés‐Genís, A., Böehm, M., Butler, J., Chioncel, O. D., Filippatos, G. S., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15408 · Cited by 28
Self-citationDiabetic cardiomyopathy revisited: The interplay between diabetes and heart failure
Mann, C., Braunwald, E., & Zelniker, T. A. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133554 · Cited by 25
Mitochondrial Dysfunction in HFpEF: Potential Interventions Through Exercise
Cui, X., Spanos, M., Zhao, C., Wan, W., Cui, C., Wang, L., & Xiao, J. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10591-5 · Cited by 20
“Patients with obesity-related HFpEF frequently exhibit metabolic syndrome or type 2 diabetes, correlating with poorer outcomesand have a worse prognosis [31].”
Lala, A., Beavers, C. J., Blumer, V. L., Brewer, L. C., Oliveira-Gomes, D. D., Dunbar, S. B., Every, H., Ferraro, R., Ky, B., Januzzi, J. L., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.06.013 · Cited by 36
Harada, T., Naser, J. A., Tada, A., Doi, S., Ibe, T., Pislaru, S. V., Eleid, M. F., Sorimachi, H., Obokata, M., Reddy, Y. N. V., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3322 · Cited by 20
“…cotransporter 2 inhibitors, 3,4 but there is also interest in therapies targeted to specific phenotypes of HFpEF, such as semaglutide for those with the obesity phenotype, 5,6 or potentially catheter ablation for those with the atrial fibrillation (AF)/left atrial (LA) myopathy phenotype.”
Self-citationXie, C., Alkhouri, N., & Elfeki, M. A. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i5.731 · Cited by 23
Habel, N., Infeld, M. M., Bernknopf, J., Meyer, M., & Lustgarten, D. L. (2023) · Heart Rhythm O2 · doi:10.1016/j.hroo.2023.12.001 · Cited by 20
“37”
Al-Najim, W., Raposo, A., BinMowyna, M. N., & le Roux, C. W. (2025) · Nutrients · doi:10.3390/nu17111934 · Cited by 16
“…muscle function may be preserved or even improved, despite decreases in muscle mass. Nonetheless, proactive strategies to maintain or enhance muscle mass, such as resistance training and adequate protein intake, may further amplify the functional benefits conferred by these pharmacotherapies [38].”
Steven, S., Kuntić, M., Münzel, T. F., & Daiber, A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100082 · Cited by 26
“277,278 The SELECT trial, a landmark study, evaluated semaglutide in over 17,000 subjects with obesity and preexisting CVD, including 4286 patients with HF.”
Cersosimo, A., Salerno, N., Sabatino, J., Scatteia, A., Bisaccia, G., Rosa, S. D., Dellegrottaglie, S., Bucciarelli‐Ducci, C., Torella, D., & Leo, I. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02181-7 · Cited by 17
“Nevertheless, treat-ment with semaglutide demonstrated to improve HF related symptoms in non-diabetic patients with HFpEF, and a recent meta-analysis encompassing eight trials and 60,080 patients demonstrated an overall reduction of HF-related hospital admission by 11% [115, 124].”
BackgroundChromatin Rewiring by SETD2 Drives Lipotoxic Injury in Cardiometabolic HFpEF
Costantino, S., Mohammed, S. A., Ambrosini, S., Telesca, M., Mengozzi, A., Walavalkar, K., Gorica, E., Herwig, M., van Heerebeek, L., Xia, J., et al. (2025) · Circulation Research · doi:10.1161/circresaha.124.325310 · Cited by 20
Yang, M., Kondo, T., Jhund, P. S., Alcocer-Gamba, M. A., Borleffs, C. J. W., Chiang, C., Colet, J. C., Desai, A. S., Dobreanu, D., Dróżdż, J., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3352 · Cited by 17
“37 The greatest geographic gradient in treatment was for MRAs which were used less often in HFpEF than HFmrEF with rates of use exceeding 40% in patients with HFmrEF in AP, LA and CEER compared to 1 8% in NA.”
Self-citationGLP-1 Receptor Agonists in Orthopaedic Surgery: Implications for Perioperative Care and Outcomes
Ramanathan, R., Lee, J. Y., Dalton, J., Lin, R. T., Lee, I., Gonzalez, C., Shaw, J. D., Schroeder, G. D., Kepler, C. K., Spitnale, M. J., et al. (2025) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.24.01287 · Cited by 17
What is the evidence regarding the safety of new obesity pharmacotherapies
Vidal, J., Flores, L., Jiménez, A., Pané, A., & de Hollanda, A. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01488-5 · Cited by 15
“The ef fi cacy and safety of GLP-1 receptor analogues in subjects with heart failure has been speci fi cally evaluated in two RCTs [51, 52].”
InfluentialGlucagon Receptor Antagonist for Heart Failure With Preserved Ejection Fraction
Gao, C., Xiong, Z., Liu, Y., Wang, M., Wang, M., Liu, T., Liu, J., Ren, S. V., Cao, N., Yan, H., et al. (2024) · Circulation Research · doi:10.1161/circresaha.124.324706 · Cited by 20
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Zhou, Q., Li, G., Hang, K., Li, J., Yang, D., & Wang, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061324-011832 · Cited by 16
Pugliese, N. R., Paneni, F., Tricò, D., Bacca, A. V., De Biase, N., Dalpiaz, H., Mengozzi, A., Virdis, A., Ghiadoni, L., Taddei, S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02778-6 · Cited by 16
“Never-theless, findings from the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM trials suggest that the benefits of semaglutide may be independent of BMI category or diabetes status [37, 139–141] (Fig.”
Aristizábal-Colorado, D., Corredor-Rengifo, D., Sierra-Castillo, S., López-Corredor, C., Trujillo, D. A. V., Weir-Restrepo, D., Izquierdo‐Condoy, J. S., Ortiz‐Prado, E., Rico-Fontalvo, J. E., Gomez‐Mesa, J., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1605746 · Cited by 37
The Role of Obesity as a Cardiac Disease Risk Factor in Patients with Type 2 Diabetes
Koirala, S., Sunnaa, M., Bernier, T. D., & Oktay, A. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02129-z · Cited by 17
“Of note, in SELECT, STEP-HFpEF, and STEP HFpEF DM, the treatment arm received semaglutide titrated up to 2.4 mg weekly, higher than the maximum dose of 2.0 mg weekly used to treat T2DM [64, 65].”
InfluentialEisa, N., & Barood, O. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70666 · Cited by 48
Landsteiner, I., Verwerft, J., Belov, D., Verbrugge, F. H., & Lewis, G. D. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag175 · Cited by 28
“145,182 In contrast, diet alone and diet-and-exercise studies by Kitzman et al . in HFpEF showed 6.6% and 10% weight loss with 6.3% and 21.4% average improvements in 6MWD, reflecting greater increments in walking distance relative to weight loss with diet or diet and exercise interventions.”
InfluentialA big STEP for treatment of heart failure with preserved ejection fraction
Verma, S., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Petrie, M. C., Shah, S. J., Dhingra, N. K., & Kosiborod, M. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.08.003 · Cited by 16
Self-citationZaher, W., Rocca, D. G. D., Pannone, L., Bovéda, S., de Asmundis, C., Chierchia, G., & Sorgente, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051316 · Cited by 18
“This is supported by the STEP-HFpEF trial, endorsing the use of Semaglutide in HFpEF patients with an obesity phenotype [127].”
MethodMcIntyre, R. S., & Kwan, A. T. H. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2430306 · Cited by 22
iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025
Chopra, V., Khan, M. S., Abdelhamid, M., Abraham, W. T., Amir, O., Anker, S. D., Atherton, J. J., Bacal, F., von Bardeleben, R. S., Brito, D. A., et al. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.05.094 · Cited by 34
Self-citationYang, M., Kondo, T., Talebi, A., Jhund, P. S., Docherty, K. F., Claggett, B. L., Vaduganathan, M., Bachus, E., Hernandez, A. F., Lam, C. S. P., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3263 · Cited by 20
Self-citationSarzani, R., Landolfo, M., Pentima, C. D., Ortensi, B., Falcioni, P., Sabbatini, L., Massacesi, A., Rampino, I., Spannella, F., & Giulietti, F. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1365183 · Cited by 26
Zhang, M., Yue, X., Xu, S., Piao, J., Zhao, L., Shu, S., Kuzuya, M., Li, P., Hong, L., Kim, W., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202400158r · Cited by 18
Leveraging metabolism for better outcomes in heart failure
Ng, Y. H., Koay, Y. C., Marques, F. Z., Kaye, D. M., & O’Sullivan, J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae216 · Cited by 20
GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization
Hu, Y., Zhao, Y., Dai, N., Zhou, Y., Yao, Y., Li, Z., Cai, W., Xiong, W., Song, S., Deng, X., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehaf1066 · Cited by 24
Re-evaluating the concept of remission in type 2 diabetes: a call for patient-centric approaches
Khunti, K., Papamargaritis, D., Aroda, V. R., Anjana, R. M., & Kashyap, S. R. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00134-2 · Cited by 22
Vaduganathan, M., Claggett, B. L., Chatur, S., Desai, A. S., Jhund, P. S., Vardeny, O., Merkely, B. P., Martínez, F. A., Colet, J. C., Saraiva, J. F. K., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04037-3 · Cited by 20
Self-citationPoly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 17
“…heart failure with preserved ejection fraction and obesity, those who received semaglutide (Wegovy 2.4 mg) had not only a greater weight loss compared to placebo, but also a 20% reduction in cardiovascular events and greater improvement in exercise function than those who received placebo [95–97].”
InfluentialGuidelines for treating heart failure
Kittleson, M. M. (2024) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2024.10.002 · Cited by 19
Liraglutide alleviates experimental diabetic cardiomyopathy in a PDH-dependent manner
Chan, J. S. F., Greenwell, A. A., Saed, C. T., Stenlund, M. J., Mangra-Bala, I. A., Dakhili, S. A. T., Yang, K., Ferrari, S. R., Eaton, F., Gopal, K., et al. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0032 · Cited by 17
Kaul, S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.036 · Cited by 19
Autonomic Nervous System: A Therapeutic Target for Cardiac End-Organ Damage in Hypertension
Gottlieb, L. A., Mahfoud, F., Stavrakis, S., Jespersen, T., & Linz, D. (2024) · Hypertension · doi:10.1161/hypertensionaha.123.19460 · Cited by 23
Beyond Weight Loss: the Emerging Role of Incretin-Based Treatments in Cardiometabolic HFpEF
Capone, F., Nambiar, N., & Schiattarella, G. G. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001117 · Cited by 15
“Among the many classes of drugs that have been tested in patients with HFpEF, only two were able to improve clinical outcomes [1,2,3 && ].”
BackgroundShokravi, A., Seth, J., Lu, N., & Mancini, G. B. J. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00248-2 · Cited by 17
“Baseline information on the 11 newly included trials [7, 8, 41–49] can be found in Supplementary Table S2.”
Doiron, J. E., Xia, H., Yu, X., Nevins, A., LaPenna, K. B., Sharp, T. E., Goodchild, T. T., Allerton, T. D., Elgazzaz, M., Lazartigues, E. D., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16493 · Cited by 15
Self-citationFabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies
Thompson, S., Roy, A., Geberhiwot, T., Gehmlich, K., & Steeds, R. P. (2025) · Biomedicines · doi:10.3390/biomedicines13030624 · Cited by 24
GLP-1-based therapeutics for cardiorenal protection in metabolic diseases
Apperloo, E. M., Heerspink, H. J. L., van Raalte, D. H., & Muskiet, M. H. A. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf110 · Cited by 25
“Also, in STEP-HFpEF, semaglutide improved symptoms, physical limitations and exercise function in 529 obese non-diabetic patients with HFpEF [34 ].”
Towards a phenotype profiling of the patients with heart failure and preserved ejection fraction
Bonfioli, G. B., Pagnesi, M., Calò, L., & Metra, M. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae095 · Cited by 20
“21,22 A pooled analysis of these two trials demonstrated an improvement of QoL and functional capacity, as well as of the secondary hierarchical composite endpoint of all-cause death, HF events, and differences in changes in KCCQ-CSS and 6 min walk distance, with a win ratio of 1.65 (1.42–1.91).”
InfluentialEl‐Sheikh, M., Caidi, N. O. E., Kandiah, A., Tonning, S. H., Taraldsen, I. A., Wisborg, F. D., Andersen, O., Hove, J. D., & Grand, J. (2025) · Cardiac failure review · doi:10.15420/cfr.2024.35 · Cited by 20
“9–11 In addition, although not primarily a weight loss study, the SELECT trial of semaglutide in patients with cardiovascular (CV) disease (almost one-quarter with HF) and BMI ≥27 kg/m², but no history of diabetes, showed improved CV outcomes.”
Bae, J. P., Kallenbach, L., Nelson, D. R., Lavelle, K., Winer-Jones, J. P., Bonafede, M., & Murakami, M. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01589-2 · Cited by 22
“…glucagon-like peptide 1 agonist and supported by the results of a recent study demonstrating that treatment with semaglutide 2.4 mg weekly led to larger reductions in symptomatic and physical burdens, greater improvements in functional capacity than placebo in patients with HFpEF and obesity [34].”
ResultInfluentialMirzai, S., Sandesara, U. B., Haykowsky, M. J., Brubaker, P. H., Kitzman, D. W., & Peters, A. E. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10526-x · Cited by 22
“These benefits may stem, in part, from significant weight loss, which reduces the hemodynamic burden on the heart and provides potent anti-inflammatory effects that counteract systemic inflammation [99].”
Self-citationGarcía‐Vega, D., Cinza‐Sanjurjo, S., Eirás, S., & González‐Juanatey, J. R. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.04.032 · Cited by 17
Obesity, Metabolic Syndrome, and Obesity Paradox in Heart Failure: A Critical Evaluation
Catalfamo, V. J., Tutor, A. W., Koos, A., Vyas, A., Lavie, C. J., & Carbone, S. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-024-00690-w · Cited by 18
“More interestingly, treatment with semaglutide demonstrated improved functional capacity, with respect to performance on 6-minute walk tests [ 35].”
Heart Failure with Preserved Ejection Fraction — A Metabolic Disease?
Pinto, Y. M. (2023) · New England Journal of Medicine · doi:10.1056/nejme2309294 · Cited by 17
Ippolito, B., & Levy, J. F. (2024) · Health Affairs · doi:10.1377/hlthaff.2024.00356 · Cited by 14
Obesity treatment in adolescents and adults in the era of personalized medicine
Sundbom, M., Järvholm, K., Sjögren, L., Nowicka, P., & Lagerros, Y. T. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13816 · Cited by 17
“Semaglutide reduced the risk of cardiovascular events in a large population of patients with obesity without type 2 diabetes [30] and reduced symptoms in patients with heart failure while achieving weight loss [31].”
Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases
Zeng, J., Tang, X., Qin, D., Yu, L., Zhou, X., Chi, F., Mi, J., Pan, H., Wu, J., Huang, B., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03677-4 · Cited by 28
Borlaug, B. A., Holse, C., Jung, M. H., Lincoff, A. M., Mulvagh, S. L., Stærk‐Østergaard, J., Tuttle, K. R., & Petrie, M. C. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102712 · Cited by 25
Self-citationKitzman, D. W., Lewis, G. D., Pandey, A., Borlaug, B. A., Sauer, A. J., Litwin, S. E., Sharma, K., Jorkasky, D. K., Khan, S. M., & Shah, S. J. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3305 · Cited by 23
Self-citationGLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
Migliorisi, G., Gabbiadini, R., Buono, A. D., Ferraris, M., Privitera, G., Petronio, L., Bertoli, P., Bezzio, C., & Armuzzi, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1610368 · Cited by 26
“Although liraglutide treatment led to a decrease in pro-in fl ammatory microbial species (e.g., Escherichia – Shigella, Megamonas , and Bacillus ) in DM2 patients, no statistically signi fi cant differences were observed when compared to metformin treatment.”
InfluentialMin, K.-D., Matsumoto, Y., Asakura, M., & Ishihara, M. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14811 · Cited by 16
Moreno, Ó., Reyes‐García, R., Pardo, I. M., López-Martínez, M., & Soler, M. J. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae039 · Cited by 15
Fitch, A., Gigliotti, L., & Bays, H. E. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100205 · Cited by 14
“Studies have demonstrated cardiovascular benefits with GLP-1 based therapies in patients with pre-existing cardiovascular disease or cardiovascular risk factors [29,43], including patients with heart failure with preserved ejection fraction and obesity [44,45].”
Banerjee, M. (2023) · Circulation Heart Failure · doi:10.1161/circheartfailure.123.010966 · Cited by 16
Hong, D., Song, S.-H., Shin, H., Bak, M., Kim, J., Kim, D., Kim, J. Y., Yang, J. H., Park, S.-J., Choi, J.-O., et al. (2025) · European Heart Journal - Digital Health · doi:10.1093/ehjdh/ztaf080 · Cited by 14
Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
Mangner, N., Winzer, E. B., Linke, A. H.-P., & Adams, V. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1149065 · Cited by 15
Incretin Receptor Agonism, Fat-free Mass, and Cardiorespiratory Fitness: A Narrative Review
Liu, Z., Weeldreyer, N. R., & Angadi, S. S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf335 · Cited by 21
Christensen, S. M., & Nelson, C. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100175 · Cited by 21
“Other obesity trials of semaglutide and tirzepatide show clinical improvement for adults with conditions such as heart failure [97 – 100], prediabetes [74,101,102], and knee osteoarthritis [103].”
DONALD, E. M., Driggin, E., Choe, J. Y., Batra, J., Vargas, F., Lindekens, J., Fried, J., Raikhelkar, J., Bae, D. J., Oh, K. T., et al. (2024) · Clinical Transplantation · doi:10.1111/ctr.15401 · Cited by 15
Frailty and Effects of Semaglutide in Obesity-Related HFpEF
Pandey, A., Kitzman, D. W., Chinnakondepalli, K., Patel, S., Borlaug, B. A., Butler, J., Davies, M. J., Shah, S. J., Verma, S., Rönnbäck, C., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102610 · Cited by 18
Self-citationNew Perspectives in Management of Cardiovascular Risk Among People With Diabetes
Gami, A., Blumenthal, R. S., McGuire, D. K., Sarkar, S., & Kohli, P. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.034053 · Cited by 17
Monzo, L., Savarese, G., Müllens, W., Abdin, A., Bozkurt, B., Chioncel, O. D., Hadidi, S. E., Gorter, T. M., Inciardi, R. M., Petrie, M. C., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70082 · Cited by 17
“11 ,30 A benefit was shown on a hierarchical composite end-point (death, HF events, and differences in the change in the KCCQ and 6-min walk distance).”
InfluentialSelf-citationAssociation Between Cardiometabolic Comorbidity Burden and Outcomes in Heart Failure
HAMO, C. E., Li, X., Ndumele, C. E., Mukhopadhyay, A., Adhikari, S., & Blecker, S. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.036985 · Cited by 19
Tuttle, M. L., Fang, J. C., Sarnak, M. J., & McCallum, W. I. (2024) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2024.151516 · Cited by 18
Mancusi, C., Basile, C., Spaccarotella, C., Gargiulo, G., Fucile, I., Paolillo, S., Gargiulo, P., Santoro, C., Manzi, L., Marzano, F., et al. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00629-1 · Cited by 15
“…may also prove beneficial, especially considering the high prevalence of obesity in the general population and especially in the hypertensive population, this is even more true in the light of the recent results of the use of GLP-1 receptor agonist in the STEP-HFpEF [124] and SELECT [125] trials.”
ResultBarana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
“…CV disease (SELECT trial) [24], improved physical function in adult heart failure with preserved ejection fraction (HFpEF) (STEP-HFpEF trial) [25], reduced pain and analgesics use in knee osteoarthritis (STEP-9 trial) [26], and demonstrated histological benefits in metabolic…”
Rivera, F. B., Chin, M. N. C., Pine, P. L. S., Ruyeras, M. M. J., Galang, D. J. C., Gandionco, K. M., Morales, B. L. F. D., Climaco, Z. M. V., Bantayan, N. R. B., Magalong, J. V., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2442027 · Cited by 19
Okuno, T., Kagami, K., Harada, T., Hoshiga, M., Ishii, H., & Obokata, M. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0214 · Cited by 20
Cornelissen, V., Hanssen, H., Hurst, C., Knaier, R., Marqués‐Sulé, E., Moholdt, T. T., Neunhäeuserer, D., Norman, K., Pedretti, R. F. E., Salzwedel, A., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf432 · Cited by 17
Hegedűs, Z. I., Jakab, M. E., Gergely, T. G., Sayour, N. V., Kovács, A., Antal, S., Kovács, T., Ferdinándy, P., Varga, Z. V., & Tóth, V. É. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02806-5 · Cited by 18
“Moreover, decreased levels of CRP was associated with GLP-1RA treatment in clinical trials [5, 11].”
Zhang, M., Lin, C., Cai, X., Jiao, R., Bai, S., Li, Z., Lv, F., Yang, W., Liu, G., Yang, X., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16078 · Cited by 15
“56 Several potential mechanisms might be responsible for these observations.”
Saw, E. L., Werner, L. D., Cooper, H. L., Pimental, D. R., Zamani, P. L., Chirinos, J. A., Valero‐Muñoz, M., & Sam, F. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.012350 · Cited by 16
Ostrominski, J. W., Solomon, S. D., & Vaduganathan, M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae414 · Cited by 16
Heart failure and obesity: novel insights leading to new treatment paradigms
Meems, L. M. G., van Veldhuisen, D. J., Sattar, N. A., & Lee, M. M. Y. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01190-7 · Cited by 20
“In the STEP-HFpEF 127,128 and STEP-HFpEF DM 129 trials, semaglutide reduced body weight, improved health status and exercise function, reduced N-terminal pro-B-type natriuretic peptide and C-reactive protein levels and reduced the use of loop diuretics.”
GLP-1 Receptor Agonists in Heart Failure
Rahmani, A. R., Dhaliwal, S., Pastena, P., Kazakov, E., Jayaseelan, K., & Kalogeropoulos, A. P. (2025) · Biomolecules · doi:10.3390/biom15101403 · Cited by 19
“The STEP-HFpEF trial demonstrated that semaglutide significantly improved symptoms, physical function, and quality of life in patients with HFpEF and obesity, with benefits observed regardless of diabetes status [14].”
InfluentialContemporary treatment options in heart failure with preserved ejection fraction
Peikert, A., & Solomon, S. D. (2024) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeae201 · Cited by 15
Matsumoto, C., Nagai, M., Shinohara, K., Morikawa, N., Kai, H., & Arima, H. (2025) · Hypertension Research · doi:10.1038/s41440-025-02240-w · Cited by 15
Liraglutide Pretreatment Does Not Improve Acute Doxorubicin-Induced Cardiotoxicity in Rats
Tonon, C. R., Monte, M. G., Balin, P. D. S., Fujimori, A. S. S., Ribeiro, A. P. D., Ferreira, N. F., Vieira, N. M., Cabral, R. P., Okoshi, M. P., Okoshi, K., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115833 · Cited by 14
“…with a previous myocardial infarction [12], decreased hospitalization in heart failure patients [13], improved diastolic function in diabetic patients [14], and reduced physical limitation symptoms and hospitalization in patients with heart failure with preserved ejection fraction and obesity [15].”
BackgroundObesity and heart failure: exploring the cardiometabolic axis
Rayner, J. J., Abdesselam, I., Pan, J., Lewis, A., & Rider, O. J. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf090 · Cited by 17
Zheng, W., Qi, Q., Li, J., He, C., & Fan, H. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01917-z · Cited by 19
The role of multimodality imaging in diabetic cardiomyopathy: a brief review
Adel, F., & Chen, H. H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1405031 · Cited by 16
“In STEP-HFpEF, heart failure hospitalization, as an exploratory end-point, seemed to be lower in the semaglutide group compared to placebo (59).”
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 21
GLP-1 RA for cardiometabolic risk reduction in obesity – How do we best describe benefit and value?
Kumar, S., & Blaha, M. J. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100682 · Cited by 13
“A total of 529 patients participated in the trial, and the results showed that in patients with HFPEF and obesity, semaglutide treatment reduced symptoms and physical limitations, improved exercise function, and reduced body weight [10].”
BackgroundResultChi, K.-Y., Song, J., Desphande, S., Lee, P., Soni, A., Gonzales-Uribe, A., Lessa, Y., Morgan, A. A., Chang, Y., Lin, Y.-S., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.17541 · Cited by 14
Visceral obesity and HFpEF: targets and therapeutic opportunities
Li, Y., Lin, Z., & Li, Y. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.02.005 · Cited by 13
Obesity and Atrial Fibrillation: From Mechanisms to Treatment
Dziano, J. K., Ariyaratnam, J., Middeldorp, M. E., Sanders, P., & Elliott, A. D. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.08.003 · Cited by 17
Metadata
- Authors
- Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., Shah, S. J., Treppendahl, M. B., Verma, S., Abhayaratna, W., Ahmed, F. Z., Chopra, V., Ezekowitz, J., Fu, M., Ito, H., Lelonek, M., Melenovsky, V., Merkely, B., Núñez, J., Perna, E., Schou, M., Senni, M., Sharma, K., Van der Meer, P., von Lewinski, D., Wolf, D., & Petrie, M. C.
- Affiliations
- University of Copenhagen (DK)
- From the Department of Cardiovascular Disease, Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City School of Medicine, Kansas City (M.N.K.); Novo Nordisk, Søborg (S.Z.A., S.R., G.K.H., M.L.L., D.V.M., M.B.T.), and the Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev (M. Schou) — both in Denmark; the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.); Baylor Scott and White Research Institute, Dallas (J.B.); the Department of Medicine, University of Mississippi, Jackson (J.B.); Diabetes Research Centre, University of Leicester, and National Institute for Health and Care Research Leicester Biomedical Research Centre (M.D.), Leicester, the Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester (F.Z.A.), and the School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (M.C.P.) — all in the United Kingdom; the Department of Cardiovascular Medicine ...
- ORCID
- Kosiborod, Mikhail N.
- Borlaug, Barry A.
- Butler, Javed
- Davies, Melanie
- Hovingh, G. Kees
- Kitzman, Dalane W.
- Shah, Sanjiv J.
- Verma, Subodh
- Abhayaratna, Walter
- Ahmed, Fozia Z.
- Chopra, Vijay
- Ezekowitz, Justin
- Fu, Michael
- Ito, Hiroshi
- Lelonek, Małgorzata
- Merkely, Bela
- Núñez, Julio
- Perna, Eduardo
- Schou, Morten
- Senni, Michele
- Sharma, Kavita
- Wolf, Dennis
- Petrie, Mark C
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-21
- Volume
- 389
- Issue
- 12
- Pages
- 1069-1084
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4386154055
- Cited by
- 1,669
- References
- 41
- Citations by year
- 2026: 548 · 2025: 597 · 2024: 461 · 2023: 61
- FWCI
- 327.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Explorer (The University of Manchester) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, heart failure with preserved ejection fraction, obesity, weight loss, Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, C-reactive protein, GLP-1 receptor agonists, heart failure events, body weight, symptom burden
- MeSH terms
- Semaglutide, Glucagon-Like Peptides, Heart Failure, Humans, Obesity, Stroke Volume
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.